These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31259797)

  • 1. Clinical care of women with intermediate breast cancer risk.
    Pederson HJ
    Menopause; 2019 Jul; 26(7):797-799. PubMed ID: 31259797
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalized assessment and management of women at risk for breast cancer in North America.
    Pruthi S; Heisey R; Bevers T
    Womens Health (Lond); 2015 Mar; 11(2):213-23; quiz 223-4. PubMed ID: 25776295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current perspective of chemoprevention in breast cancer].
    Asaga S; Jinno H; Sakata M; Kitajima M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():627-32. PubMed ID: 17682221
    [No Abstract]   [Full Text] [Related]  

  • 4. The breast cancer chemoprevention debate.
    Schmidt C
    J Natl Cancer Inst; 2011 Nov; 103(22):1646-7. PubMed ID: 22025628
    [No Abstract]   [Full Text] [Related]  

  • 5. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing breast cancer risk: genetic factors are not the whole story.
    Korde LA; Calzone KA; Zujewski J
    Postgrad Med; 2004 Oct; 116(4):6-8, 11-4, 19-20. PubMed ID: 15510590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
    Mocellin S; Pilati P; Briarava M; Nitti D
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model.
    Gail MH
    J Natl Cancer Inst; 2009 Jul; 101(13):959-63. PubMed ID: 19535781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer prevention.
    Euhus DM; Diaz J
    Breast J; 2015; 21(1):76-81. PubMed ID: 25413630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of breast cancer: new approaches.
    Cummings SR
    Maturitas; 2007 May; 57(1):39-41. PubMed ID: 17391879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.
    MacDonald DJ; Sarna L; Uman GC; Grant M; Weitzel JN
    Oncol Nurs Forum; 2006 Nov; 33(2):E27-35. PubMed ID: 16518435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer prevention: lifestyle changes and chemoprevention.
    Lambrechts S; Decloedt J; Neven P
    Acta Clin Belg; 2011; 66(4):283-92. PubMed ID: 21938984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of breast cancer among women at elevated risk as defined by Gail Score.
    Micallef S; Micallef D; Schembri-Wismayer P; Brincat MP; Calleja-Agius J
    Minerva Ginecol; 2015 Aug; 67(4):335-52. PubMed ID: 25668503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.
    Vachon CM; Ingle JN; Suman VJ; Scott CG; Gottardt H; Olson JE; Goss PE
    Breast; 2007 Apr; 16(2):204-10. PubMed ID: 17145182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer prevention in high-risk women: searching for new options.
    Nelson NJ
    J Natl Cancer Inst; 2011 May; 103(9):710-1. PubMed ID: 21515834
    [No Abstract]   [Full Text] [Related]  

  • 16. Tamoxifen, mammographic density, and breast cancer prevention.
    Boyd NF
    J Natl Cancer Inst; 2011 May; 103(9):704-5. PubMed ID: 21487099
    [No Abstract]   [Full Text] [Related]  

  • 17. [Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
    Eiermann W
    MMW Fortschr Med; 2003 Dec; 145(50):8. PubMed ID: 14963963
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical management of women at high risk of breast cancer.
    Wuttke M; Phillips KA
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):6-13. PubMed ID: 25502281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for aromatase inhibition in breast cancer prevention.
    Lønning PE; Kragh LE; Erikstein B; Hagen A; Risberg T; Schlichting E; Geisler J
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4423s-4428s; discussion 4411s-4412s. PubMed ID: 11916235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF; Chlebowski RT
    Menopause; 2008; 15(4 Suppl):804-9. PubMed ID: 18596602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.